Noticias y vídeos - EDITAS MEDICINE INC.

Company aligned with FDA that RUBY is a single Phase 1/2/3 trial On track to present additional clinical data from the RUBY trial and the EdiTHAL trial of reni-cel in mid-2024 and additional updates by year-end 2024 Initiated enrollment in the adolescent cohort in the RUBY trial Entered into a license agreement providing Vertex Pharmaceuticals a non-exclusive license for Cas9 Strong financial position with operational runway expected into 2026 CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) --...

CAMBRIDGE, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it will host a conference call and webcast on Wednesday, February 28, 2024, at 8:00 a.m. ET to discuss results for the fourth quarter and full year 2023 and to provide a corporate update. To access the conference call: U.S. callers should dial +1-877-407-0989 and international callers should dial +1-201-389-0921 approximately five minutes before...

CAMBRIDGE, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that management will participate in the following upcoming investor conferences to discuss the Company and its programs, including reni-cel: Guggenheim 6th Annual Biotechnology Conference Format: Fireside Chat Date: Wednesday, February 7 Time: 9:30 a.m. ET Location: New York, NY Oppenheimer 34th Annual Healthcare Life Sciences Conference Format:...

Anticipated 2024 milestones include: present reni-cel clinical data updates mid-year and year-end, initiate the RUBY clinical trial adolescent cohort, establish in vivo preclinical proof-of-concept for an undisclosed indication , and continue to sublicense foundational IP Strong financial position with operational runway into 2026 Company to present at the 42 nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9 at 4:30 p.m. PST CAMBRIDGE, Mass., Jan. 08, 2024 (GLOBE NEWSWIRE) --...

CAMBRIDGE, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that the Company’s President and CEO Gilmore O’Neill, M.B., M.M.Sc., will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, 4:30 p.m. PT / 7:30 p.m. ET in San Francisco, CA. A live webcast of the presentation will be available on the “Investors” section of the Editas Medicine website at...

Vertex Pharmaceuticals to obtain a non-exclusive license for Cas9 f or CASGEVY™ (exagamglogene autotemcel) Agreement extends Editas Medicine’s cash runway into 2026 CAMBRIDGE, Mass., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that the Company and Vertex Pharmaceuticals entered into a license agreement. Under terms of the agreement, Vertex will obtain a non-exclusive license for Editas Medicine’s Cas9 gene...

All RUBY patients with ≥5 months follow-up have achieved a normal hemoglobin level and a fetal hemoglobin level of >40% All patients treated in the RUBY trial are free of vaso-occlusive events post-EDIT-301 infusion EDIT-301 was well-tolerated and demonstrated a safety profile consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem cell transplant EDIT-301 is now known as renizgamglogene autogedtemcel (reni-cel) Company-sponsored webinar on the RUBY and...

Company to provide a clinical update on the EDIT-301 RUBY trial for SCD and EdiTHAL trial for TDT in December at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored webinar Granted Vor Bio a non-exclusive license for Cas9 patents for ex vivo HSC therapies for the treatment and prevention of hematological malignancies Strengthened Executive Team with appointment of Caren Deardorf as the Company's first Chief Commercial and Strategy Officer CAMBRIDGE, Mass., Nov. 03,...

Company to host a webinar to discuss EDIT-301 clinical data on Monday, December 11, at 1:00 p.m. ET Dr. Rabi Hanna from Cleveland Clinic Children’s to present EDIT-301 clinical data at ASH on Monday, December 11 CAMBRIDGE, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that a scientific abstract detailing safety and efficacy clinical data from the RUBY trial of EDIT-301 in patients with severe sickle cell...

CAMBRIDGE, Mass., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it will host a conference call and webcast on Friday, November 3, 2023, at 8:00 a.m. ET to discuss results for the third quarter 2023 and to provide a corporate update. To access the conference call: U.S. callers should dial +1-877-407-0989 and international callers should dial +1-201-389-0921 approximately five minutes before the call begins....

CAMBRIDGE, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to EDIT-301, an investigational, gene editing medicine, for the treatment of severe sickle cell disease (SCD). “Sickle cell disease is a devastating disease that leads to anemia, pain crises, organ failure, and early death. Receiving...

CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the grant of an inducement award to the Company’s newly appointed Chief Commercial and Strategy Officer, Caren Deardorf. In connection with Ms. Deardorf’s appointment, the Editas Medicine Board of Directors approved a stock option grant to Ms. Deardorf as an inducement material to Ms. Deardorf entering into employment with Editas Medicine in...

CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the appointment of Caren Deardorf as the Company’s first Chief Commercial and Strategy Officer. Ms. Deardorf will build and lead Editas Medicine’s commercial organization, strategy, and execution to support all launch, commercialization, and lifecycle management activities of the Company’s current and future pipeline of products. “As we drive...

CAMBRIDGE, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that management will participate in the following upcoming investor conferences: 2023 Wells Fargo Healthcare Conference Format: Fireside Chat Date: Thursday, September 7 Time: 3:00 p.m. ET Location: Boston, MA Morgan Stanley 21st Annual Global Healthcare Conference Format: Fireside Chat Date: Monday, September 11 Time: 10:00 a.m. ET Location: New...

On track to dose 20 total patients in the EDIT-301 RUBY trial for SCD and provide a clinical update by year-end Commenced parallel patient dosing in the EDIT-301 EDITHAL trial for TDT and on track to provide a clinical update by year-end Strengthened Executive Team with Appointments of Erick Lucera as Chief Financial Officer and Linda C. Burkly, Ph.D., as Chief Scientific Officer CAMBRIDGE, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome...

Editas Medicine and Azzur Group Expand Partnership to Accelerate Editas' Manufacturing Capabilities for Advancing the EDIT-301 Program Through Approval to Commercialization PR Newswire CAMBRIDGE, Mass., and DEVENS, Mass., July 27, 2023 CAMBRIDGE, Mass. , and DEVENS, Mass. , July 27, 2023 /PRNewswire/ -- Editas Medicine , Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, and Azzur Cleanrooms on Demand™ (COD), an Azzur Group company, today announced the companies have expanded their...

CAMBRIDGE, Mass., and DEVENS, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Editas Medicine , Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, and Azzur Cleanrooms on Demand™ (COD), an Azzur Group company, today announced the companies have expanded their multi-year contract to support the scaling of EDIT-301, Editas Medicine’s experimental cell therapy medicine under investigation for the treatment of severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT),...

CAMBRIDGE, Mass., July 26, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it will host a conference call and webcast on Wednesday, August 2, 2023, at 8:00 a.m. ET to discuss results for the second quarter 2023 and to provide a corporate update. To access the conference call: U.S. callers should dial +1-877-407-0989 and international callers should dial +1-201-389-0921 approximately five minutes before the call begins....

CAMBRIDGE, Mass., July 25, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced the grant of an inducement award to the Company’s newly appointed Chief Scientific Officer, Linda C. Burkly, Ph.D. In connection with Dr. Burkly’s appointment, the Editas Medicine Board of Directors approved a stock option grant to Dr. Burkly as an inducement material to Dr. Burkly entering into employment with Editas Medicine in accordance with...

CAMBRIDGE, Mass., July 24, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the appointment of Linda C. Burkly, Ph.D., as the Company’s Executive Vice President and Chief Scientific Officer. Dr. Burkly will lead Editas’ drug discovery team and activities related to Editas Medicine’s pipeline of experimental medicines across all therapeutic areas and indications. “Earlier this year, we shared our vision to be a leader...